Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease ; volume:12 ; number:1 ; day:22 ; month:1 ; year:2020 ; pages:1-12 ; date:12.2020
Alzheimer's research & therapy ; 12, Heft 1 (22.1.2020), 1-12, 12.2020

Creator: Yoshida, Kenta
Moein, Anita
Bittner, Tobias
Ostrowitzki, Susanne
Lin, Helen
Honigberg, Lee
Jin, Jin Y.
Quartino, Angelica

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13195-020-0580-2

URN: urn:nbn:de:101:1-2020042501223659929196

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:51 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Yoshida, Kenta
Moein, Anita
Bittner, Tobias
Ostrowitzki, Susanne
Lin, Helen
Honigberg, Lee
Jin, Jin Y.
Quartino, Angelica
SpringerLink (Online service)

Other Objects (12)

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

Hochschulschrift

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Hochschulschrift

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Metabolite profiling of Alzheimer's disease cerebrospinal fluid

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

Hochschulschrift

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Hochschulschrift

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Metabolite profiling of Alzheimer's disease cerebrospinal fluid

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

Hochschulschrift

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Hochschulschrift

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Metabolite profiling of Alzheimer's disease cerebrospinal fluid

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Metabolite profiling of Alzheimer's disease cerebrospinal fluid

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Metabolite profiling of Alzheimer's disease cerebrospinal fluid

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease

Increased Levels of Antigen-Bound beta-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer’s disease

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Selektion hochaffiner RNA-Moleküle gegen das Alzheimer β-Amyloid [Beta-Amyloid]

Metabolite profiling of Alzheimer's disease cerebrospinal fluid

Related objects

Reset password